Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Seer (Nasdaq: SEER) will showcase its AI-driven multi-cancer screening approach and next-generation proteomics tools at ASMS 2026 in San Diego, May 31–June 4.
Highlights include a 20,000-sample collaboration with Korea University, the Radiant DIA™ search engine, the Fulcrum Pipeline™, and numerous customer-led Proteograph® studies.
Seer (Nasdaq: SEER) announced that its Board of Directors unanimously rejected a further revised unsolicited, non-binding acquisition proposal from the Radoff-JEC Group received on May 14, 2026.
The offer was for $2.40 per share in cash plus a contingent value right. The Board, advised by independent financial and legal advisors, determined the proposal significantly undervalues Seer, does not reflect its long-term growth prospects, and implies an equity value meaningfully below the sum of its current cash, cash equivalents and investments.
Summary not available.
Seer (Nasdaq: SEER) reported first quarter 2026 revenue of $2.8 million, down 34% year-over-year, with gross margin of 35% and net loss of $16.8 million. Operating expenses fell 20% to $18.2 million. The company ended the quarter with about $220 million in cash and investments and reaffirmed 2026 revenue guidance of $16–$18 million.
Seer highlighted a major collaboration in Singapore covering 10,000 samples, a doubling of independent publications to 84, a U.S. patent office decision reinforcing its IP position, and repurchase of about 1.5 million Class A shares.
Summary not available.
Seer (Nasdaq: SEER) appointed Anthony Bazarko as Chief Commercial Officer on May 4, 2026. Bazarko brings more than two decades of commercial leadership and will lead Sales, Marketing, and Customer Experience to accelerate adoption of the Proteograph® Product Suite.
Bazarko served as President and CEO of Biologos (2022–2025), was CCO at Specific Diagnostics, and held senior commercial roles at Danaher and Roche.
Seer products are for research use only and are not diagnostic.
Seer (Nasdaq: SEER) will report first-quarter 2026 financial results on May 13, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be on the Investor section of Seer's website and an archived replay will follow.